# An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)

> **NCT01739348** · PHASE2,PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 2211 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Verubecestat (Part I and Part II)
- **DRUG:** Verubecestat (Part I and Part II)
- **DRUG:** Verubecestat (Part I and Part II)
- **DRUG:** Placebo (Part I)
- **DRUG:** Verubecestat (Part II)

## Key facts

- **NCT ID:** NCT01739348
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11-30
- **Primary completion:** 2017-04-14
- **Final completion:** 2017-04-14
- **Target enrollment:** 2211 (ACTUAL)
- **Last updated:** 2018-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01739348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01739348, "An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01739348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*